2017 American Transplant Congress
ABO-Incompatibility Using Ritiuximab Does Not Increase Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Background and aims: ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) has a high success rate. However, a difference in hepatocellular carcinoma (HCC) recurrence rates has…2017 American Transplant Congress
Comparison of Long-Term Survival Outcome Between Primary Liver Transplantation and Hepatic Resection with Consequent Salvage Transplantation for Hepatocellular Carcinoma within Milan Criteria – A Single-Center Experience.
Background: Whether primary liver transplantation (PLT) is superior to the upfront hepatic resection (HR) and salvage liver transplantation (SLT) for hepatocellular carcinoma (HCC) within Milan…2017 American Transplant Congress
Women in the United States Receive More Resections and Ablations for Hepatocellular Carcinoma Than Men.
1The Ohio State Wexner Medical Center, Columbus; 2The Ohio State University, Columbus
Background: Previous studies have shown conflicting data regarding gender disparities in the treatment of hepatocellular carcinoma. Several studies have suggested that men are more likely…2017 American Transplant Congress
Comparison of Local Recurrence Rates Between Endhole vs Anti-Reflux Catheters in Patients Undergoing DEB-TACE for Solitary LR-5 HCC Tumors.
PurposeTo compare local recurrence rates (LRR), tumor response rates, and dose delivered between standard endhole catheters (EC) versus anti-reflux catheters (AR) in patients who underwent…2017 American Transplant Congress
Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma within Milan Criteria.
Introduction: The systemic inflammation biomarker, neutrophil-to-lymphocyte ratio (NLR) has been reported to be a predioctor of poor survival in patients with various cancers. The purpose…2017 American Transplant Congress
Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect.
Introduction: Liver transplantation (LT) is increasing treatment option for hepatocellular carcinoma (HCC) in East Asia. Over-immunosuppression is risk factor for oncologic outcome after transplantation and…2017 American Transplant Congress
The Impact of the Donor Risk Index on Tumor Free Survival in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma.
In this study, we look at the impact of donor quality on tumor free survival in patients undergoing liver transplant (LT) with hepatocellular carcinoma (HCC)…2017 American Transplant Congress
Outcomes Following Transplantation for Hepatocellular Carcinoma.
Transplant, Recanati/Miller Transplantation Institute, New York, Ny
Objectives: To examine the prognostic features and outcomes of patients undergoing transplantation for hepatocellular carcinoma (HCC).Methods: A single-institution retrospective chart review was performed on all…2017 American Transplant Congress
Effect of Embolization History and Tumor Treatment Response on Plasma TGFβ in HCC Patients Listed for Liver Transplantation.
Purpose: TGFβ signaling is an integral pathway in hepatocellular carcinoma (HCC) metastasis. In this study, we monitored TGFβ levels and imaging response in HCC patients…2017 American Transplant Congress
Expanded Criteria for HCC in Liver Transplantation.
Introduction: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third highest cause of death related to malignancy. Since HCC diagnosis is…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 23
- Next Page »